|remdesivir nih pubmed||1.18||0.1||3445||85|
Remdesivir is available through an FDA EUA for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg. A clinical trial is currently evaluating the pharmacokinetics of remdesivir in children ( ClinicalTrials.gov Identifier NCT04431453 ).How effective is remdesivir for the treatment of covid-19?
Remdesivir for the Treatment of Covid-19 - Final Report Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.What is a valid warning or clinical lore for remdesivir?
A valid warning or clinical lore: an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrob Agents Chemother. 2021;65 (2).Is remdesivir safe for pregnant patients?
Pregnant patients were excluded from the clinical trials that evaluated the safety and efficacy of remdesivir for the treatment of COVID-19, but preliminary reports of remdesivir use in pregnant patients from the remdesivir compassionate use program are reassuring.